Controlled Ovarian Stimulation Protocols in Cancer Patients

  • Hakan CakmakEmail author
  • Mitchell P. Rosen


Embryo/oocyte cryopreservation is an effective method for fertility preservation in cancer patients. Determination of the controlled ovarian stimulation protocol and gonadotropin dose for oocyte/embryo cryopreservation requires an individualized assessment. Maximizing the number of embryos and oocytes cryopreserved during a fertility preservation cycle without causing ovarian hyperstimulation syndrome is extremely important, because the most of the patients have a single cycle opportunity due to time constraints before starting their oncologic treatment. In emergent settings, random-start ovarian stimulation is emerging as a new technique for the purpose of fertility preservation without compromising oocyte yield and maturity. Ovarian stimulation with tamoxifen or letrozole is highly recommended in patients with estrogen-sensitive cancers undergoing fertility preservation. While only a minority of the cancer patients has undergone thawing and embryo transfer, recent data of these modified protocols in egg donors and infertile patients have suggested that pregnancy outcomes are similar to those of conventional protocols.


Cancer Controlled ovarian stimulation Random-start ovarian stimulation Fertility preservation Oocyte/embryo cryopreservation 


  1. 1.
    Howlader N, Noone AM, Krapcho M, Neyman N, Aminou R, Waldron W, Altekruse SF, Kosary CL, Ruhl J, Tatalovich Z, Cho H, Mariotto A, Eisner MP, Lewis DR, Chen HS, Feuer EJ, Cronin KA (eds). SEER cancer statistics review, 1975–2009 (Vintage 2009 populations), National Cancer Institute. Bethesda. Available at: Accessed on 16 June 2015
  2. 2.
    Letourneau JM, Ebbel EE, Katz PP, Katz A, Ai WZ, Chien AJ, Melisko ME, Cedars MI, Rosen MP (2012) Pretreatment fertility counseling and fertility preservation improve quality of life in reproductive age women with cancer. Cancer 118(6):1710–1717CrossRefPubMedGoogle Scholar
  3. 3.
    Letourneau JM, Melisko ME, Cedars MI, Rosen MP (2011) A changing perspective: improving access to fertility preservation. Nat Rev Clin Oncol 8(1):56–60CrossRefPubMedGoogle Scholar
  4. 4.
    Rodriguez-Wallberg KA, Oktay K (2012) Options on fertility preservation in female cancer patients. Cancer Treat Rev 38(5):354–361CrossRefPubMedGoogle Scholar
  5. 5.
    Letourneau JM, Ebbel EE, Katz PP, Oktay KH, McCulloch CE, Ai WZ, Chien AJ, Melisko ME, Cedars MI, Rosen MP (2012) Acute ovarian failure underestimates age-specific reproductive impairment for young women undergoing chemotherapy for cancer. Cancer 118(7):1933–1939CrossRefPubMedGoogle Scholar
  6. 6.
    Maltaris T, Seufert R, Fischl F, Schaffrath M, Pollow K, Koelbl H, Dittrich R (2007) The effect of cancer treatment on female fertility and strategies for preserving fertility. Eur J Obstet Gynecol Reprod Biol 130(2):148–155CrossRefPubMedGoogle Scholar
  7. 7.
    Wallace WH, Thomson AB, Kelsey TW (2003) The radiosensitivity of the human oocyte. Hum Reprod 18(1):117–121CrossRefPubMedGoogle Scholar
  8. 8.
    Meirow D, Nugent D (2001) The effects of radiotherapy and chemotherapy on female reproduction. Hum Reprod Update 7(6):535–543CrossRefPubMedGoogle Scholar
  9. 9.
    The Practice Committee of the American Society for Reproductive Medicine (2005) Fertility preservation and reproduction in cancer patients. Fertil Steril 83(6):1622–1628CrossRefGoogle Scholar
  10. 10.
    The Practice Committee of the American Society for Reproductive Medicine (2013) Mature oocyte cryopreservation: a guideline. Fertil Steril 99(1):37–43CrossRefGoogle Scholar
  11. 11.
    McLaren JF, Bates GW (2012) Fertility preservation in women of reproductive age with cancer. Am J Obstet Gynecol 207(6):455–462CrossRefPubMedGoogle Scholar
  12. 12.
    Schachter M, Friedler S, Raziel A, Strassburger D, Bern O, Ron-el R (2001) Improvement of IVF outcome in poor responders by discontinuation of GnRH analogue during the gonadotropin stimulation phase – a function of improved embryo quality. J Assist Reprod Genet 18(4):197–204CrossRefPubMedGoogle Scholar
  13. 13.
    Gougeon A (1986) Dynamics of follicular growth in the human: a model from preliminary results. Hum Reprod 1(2):81–87PubMedGoogle Scholar
  14. 14.
    Pache TD, Wladimiroff JW, de Jong FH, Hop WC, Fauser BC (1990) Growth patterns of nondominant ovarian follicles during the normal menstrual cycle. Fertil Steril 54(4):638–642CrossRefPubMedGoogle Scholar
  15. 15.
    McNatty KP, Hillier SG, van den Boogaard AM, Trimbos-Kemper TC, Reichert LE Jr, van Hall EV (1983) Follicular development during the luteal phase of the human menstrual cycle. J Clin Endocrinol Metab 56(5):1022–1031CrossRefPubMedGoogle Scholar
  16. 16.
    Anderson RA, Kinniburgh D, Baird DT (1999) Preliminary experience of the use of a gonadotropin-releasing hormone antagonist in ovulation induction/in-vitro fertilization prior to cancer treatment. Hum Reprod 14(10):2665–2668CrossRefPubMedGoogle Scholar
  17. 17.
    Humaidan P, Bungum L, Bungum M, Hald F, Agerholm I, Blaabjerg J, Yding Andersen C, Lindenberg S (2005) Reproductive outcome using a GnRH antagonist (cetrorelix) for luteolysis and follicular synchronization in poor responder IVF/ICSI patients treated with a flexible GnRH antagonist protocol. Reprod Biomed Online 11(6):679–684CrossRefPubMedGoogle Scholar
  18. 18.
    von Wolff M, Thaler CJ, Frambach T, Zeeb C, Lawrenz B, Popovici RM, Strowitzki T (2009) Ovarian stimulation to cryopreserve fertilized oocytes in cancer patients can be started in the luteal phase. Fertil Steril 92(4):1360–1365CrossRefGoogle Scholar
  19. 19.
    Cakmak H, Katz A, Cedars MI, Rosen MP (2013) Effective method for emergency fertility preservation: random-start controlled ovarian stimulation. Fertil Steril 100(6):1673–1680. doi: 10.1016/j.fertnstert.2013.07.1992 CrossRefPubMedGoogle Scholar
  20. 20.
    Sonmezer M, Turkcuoglu I, Coskun U, Oktay K (2011) Random-start controlled ovarian hyperstimulation for emergency fertility preservation in letrozole cycles. Fertil Steril 95(6):2125, e2129–2111CrossRefPubMedGoogle Scholar
  21. 21.
    Bedoschi GM, de Albuquerque FO, Ferriani RA, Navarro PA (2010) Ovarian stimulation during the luteal phase for fertility preservation of cancer patients: case reports and review of the literature. J Assist Reprod Genet 27(8):491–494CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Nayak SR, Wakim AN (2011) Random-start gonadotropin-releasing hormone (GnRH) antagonist-treated cycles with GnRH agonist trigger for fertility preservation. Fertil Steril 96(1):e51–e54. doi: 10.1016/j.fertnstert.2011.04.079 CrossRefPubMedGoogle Scholar
  23. 23.
    Keskin U, Ercan CM, Yilmaz A, Babacan A, Korkmaz C, Duru NK, Ergun A (2014) Random-start controlled ovarian hyperstimulation with letrozole for fertility preservation in cancer patients: case series and review of literature. J Pak Med Assoc 64(7):830–832PubMedGoogle Scholar
  24. 24.
    Ozkaya E, San Roman G, Oktay K (2012) Luteal phase GnRHa trigger in random start fertility preservation cycles. J Assist Reprod Genet 29(6):503–505. doi: 10.1007/s10815-012-9752-8 CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Kim JH, Kim SK, Lee HJ, Lee JR, Jee BC, Suh CS, Kim SH (2015) Efficacy of random-start controlled ovarian stimulation in cancer patients. J Korean Med Sci 30(3):290–295. doi: 10.3346/jkms.2015.30.3.290 CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Cakmak H, Mok-Lin E, Katz A, Harris E, Chin-Yu C, Cedars MI, Rosen MP (2014) Random start controlled ovarian stimulation results in high oocyte developmental competence and embryo quality. Fertil Steril 102(3):e164CrossRefGoogle Scholar
  27. 27.
    Checa MA, Brassesco M, Sastre M, Gomez M, Herrero J, Marque L, Brassesco A, Espinos JJ (2015) Random-start GnRH antagonist for emergency fertility preservation: a self-controlled trial. Int J Womens Health 7:219–225. doi: 10.2147/IJWH.S66743 CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Chen H, Wang Y, Lyu Q, Ai A, Fu Y, Tian H, Cai R, Hong Q, Chen Q, Shoham Z, Kuang Y (2015) Comparison of live-birth defects after luteal-phase ovarian stimulation vs. conventional ovarian stimulation for in vitro fertilization and vitrified embryo transfer cycles. Fertil Steril 103(5):1194–1201 e1192. doi: 10.1016/j.fertnstert.2015.02.020 CrossRefPubMedGoogle Scholar
  29. 29.
    Kuang Y, Hong Q, Chen Q, Lyu Q, Ai A, Fu Y, Shoham Z (2014) Luteal-phase ovarian stimulation is feasible for producing competent oocytes in women undergoing in vitro fertilization/intracytoplasmic sperm injection treatment, with optimal pregnancy outcomes in frozen-thawed embryo transfer cycles. Fertil Steril 101(1):105–111. doi: 10.1016/j.fertnstert.2013.09.007 CrossRefPubMedGoogle Scholar
  30. 30.
    Martinez F, Clua E, Devesa M, Rodriguez I, Arroyo G, Gonzalez C, Sole M, Tur R, Coroleu B, Barri PN (2014) Comparison of starting ovarian stimulation on day 2 versus day 15 of the menstrual cycle in the same oocyte donor and pregnancy rates among the corresponding recipients of vitrified oocytes. Fertil Steril 102(5):1307–1311. doi: 10.1016/j.fertnstert.2014.07.741 CrossRefPubMedGoogle Scholar
  31. 31.
    Reddy J, Oktay K (2012) Ovarian stimulation and fertility preservation with the use of aromatase inhibitors in women with breast cancer. Fertil Steril 98(6):1363–1369CrossRefPubMedGoogle Scholar
  32. 32.
    Rodriguez-Wallberg KA, Oktay K (2010) Fertility preservation in women with breast cancer. Clin Obstet Gynecol 53(4):753–762CrossRefPubMedPubMedCentralGoogle Scholar
  33. 33.
    (1992) Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Early Breast Cancer Trialists’ Collaborative Group. Lancet 339(8785):71–85Google Scholar
  34. 34.
    Fisk NM, Templeton AA, Papadopoulos GC, Matlin SA, Wu ZY (1989) Lack of effect of high-dose antioestrogen on the maturation and in-vitro fertilization of human oocytes. Hum Reprod 4(5):584–587PubMedGoogle Scholar
  35. 35.
    Meirow D, Raanani H, Maman E, Paluch-Shimon S, Shapira M, Cohen Y, Kuchuk I, Hourvitz A, Levron J, Mozer-Mendel M, Brengauz M, Biderman H, Manela D, Catane R, Dor J, Orvieto R, Kaufman B (2014) Tamoxifen co-administration during controlled ovarian hyperstimulation for in vitro fertilization in breast cancer patients increases the safety of fertility-preservation treatment strategies. Fertil Steril 102(2):488–495 e483. doi: 10.1016/j.fertnstert.2014.05.017 CrossRefPubMedGoogle Scholar
  36. 36.
    Oktay K, Buyuk E, Davis O, Yermakova I, Veeck L, Rosenwaks Z (2003) Fertility preservation in breast cancer patients: IVF and embryo cryopreservation after ovarian stimulation with tamoxifen. Hum Reprod 18(1):90–95CrossRefPubMedGoogle Scholar
  37. 37.
    Oktay K, Buyuk E, Libertella N, Akar M, Rosenwaks Z (2005) Fertility preservation in breast cancer patients: a prospective controlled comparison of ovarian stimulation with tamoxifen and letrozole for embryo cryopreservation. J Clin Oncol 23(19):4347–4353CrossRefPubMedGoogle Scholar
  38. 38.
    Cole PA, Robinson CH (1990) Mechanism and inhibition of cytochrome P-450 aromatase. J Med Chem 33(11):2933–2942CrossRefPubMedGoogle Scholar
  39. 39.
    Smith IE, Dowsett M (2003) Aromatase inhibitors in breast cancer. N Engl J Med 348(24):2431–2442CrossRefPubMedGoogle Scholar
  40. 40.
    Mitwally MF, Casper RF (2001) Use of an aromatase inhibitor for induction of ovulation in patients with an inadequate response to clomiphene citrate. Fertil Steril 75(2):305–309CrossRefPubMedGoogle Scholar
  41. 41.
    Testart J, Frydman R, Nahoul K, Grenier J, Feinstein MC, Roger M, Scholler R (1982) Steroids and gonadotropins during the last pre-ovulatory phase of the menstrual cycle. Time relationships between plasma hormones levels and luteinizing hormone surge onset. J Steroid Biochem 17(6):675–682CrossRefPubMedGoogle Scholar
  42. 42.
    Oktay K, Hourvitz A, Sahin G, Oktem O, Safro B, Cil A, Bang H (2006) Letrozole reduces estrogen and gonadotropin exposure in women with breast cancer undergoing ovarian stimulation before chemotherapy. J Clin Endocrinol Metab 91(10):3885–3890CrossRefPubMedGoogle Scholar
  43. 43.
    Johnson LN, Dillon KE, Sammel MD, Efymow BL, Mainigi MA, Dokras A, Gracia CR (2013) Response to ovarian stimulation in patients facing gonadotoxic therapy. Reprod Biomed Online 26(4):337–344. doi: 10.1016/j.rbmo.2013.01.003 CrossRefPubMedPubMedCentralGoogle Scholar
  44. 44.
    Checa Vizcaino MA, Corchado AR, Cuadri ME, Comadran MG, Brassesco M, Carreras R (2012) The effects of letrozole on ovarian stimulation for fertility preservation in cancer-affected women. Reprod Biomed Online 24(6):606–610. doi: 10.1016/j.rbmo.2012.02.020 CrossRefPubMedGoogle Scholar
  45. 45.
    Domingo J, Guillen V, Ayllon Y, Martinez M, Munoz E, Pellicer A, Garcia-Velasco JA (2012) Ovarian response to controlled ovarian hyperstimulation in cancer patients is diminished even before oncological treatment. Fertil Steril 97(4):930–934. doi: 10.1016/j.fertnstert.2012.01.093 CrossRefPubMedGoogle Scholar
  46. 46.
    Revelli A, Porcu E, Levi Setti PE, Delle Piane L, Merlo DF, Anserini P (2013) Is letrozole needed for controlled ovarian stimulation in patients with estrogen receptor-positive breast cancer? Gynecol Endocrinol 29(11):993–996. doi: 10.3109/09513590.2013.819083 CrossRefPubMedGoogle Scholar
  47. 47.
    Klein KO, Demers LM, Santner SJ, Baron J, Cutler GB Jr, Santen RJ (1995) Use of ultrasensitive recombinant cell bioassay to measure estrogen levels in women with breast cancer receiving the aromatase inhibitor, letrozole. J Clin Endocrinol Metab 80(9):2658–2660PubMedGoogle Scholar
  48. 48.
    Azim AA, Costantini-Ferrando M, Lostritto K, Oktay K (2007) Relative potencies of anastrozole and letrozole to suppress estradiol in breast cancer patients undergoing ovarian stimulation before in vitro fertilization. J Clin Endocrinol Metab 92(6):2197–2200CrossRefPubMedGoogle Scholar
  49. 49.
    Azim AA, Costantini-Ferrando M, Oktay K (2008) Safety of fertility preservation by ovarian stimulation with letrozole and gonadotropins in patients with breast cancer: a prospective controlled study. J Clin Oncol 26(16):2630–2635CrossRefPubMedGoogle Scholar
  50. 50.
    Turan V, Bedoschi G, Moy F, Oktay K (2013) Safety and feasibility of performing two consecutive ovarian stimulation cycles with the use of letrozole-gonadotropin protocol for fertility preservation in breast cancer patients. Fertil Steril 100(6):1681–1685 e1681. doi: 10.1016/j.fertnstert.2013.08.030 CrossRefPubMedPubMedCentralGoogle Scholar
  51. 51.
    Azim A, Oktay K (2007) Letrozole for ovulation induction and fertility preservation by embryo cryopreservation in young women with endometrial carcinoma. Fertil Steril 88(3):657–664CrossRefPubMedGoogle Scholar
  52. 52.
    Tiboni GM (2004) Aromatase inhibitors and teratogenesis. Fertil Steril 81(4):1158–1159; author reply 1159. doi: 10.1016/j.fertnstert.2004.01.006 Google Scholar
  53. 53.
    Tulandi T, Martin J, Al-Fadhli R, Kabli N, Forman R, Hitkari J, Librach C, Greenblatt E, Casper RF (2006) Congenital malformations among 911 newborns conceived after infertility treatment with letrozole or clomiphene citrate. Fertil Steril 85(6):1761–1765. doi: 10.1016/j.fertnstert.2006.03.014 CrossRefPubMedGoogle Scholar
  54. 54.
    Legro RS, Brzyski RG, Diamond MP, Coutifaris C, Schlaff WD, Casson P, Christman GM, Huang H, Yan Q, Alvero R, Haisenleder DJ, Barnhart KT, Bates GW, Usadi R, Lucidi S, Baker V, Trussell JC, Krawetz SA, Snyder P, Ohl D, Santoro N, Eisenberg E, Zhang H, Network NRM (2014) Letrozole versus clomiphene for infertility in the polycystic ovary syndrome. N Engl J Med 371(2):119–129. doi: 10.1056/NEJMoa1313517 CrossRefPubMedPubMedCentralGoogle Scholar
  55. 55.
    Oktay K, Turan V, Bedoschi G, Pacheco FS, Moy F (2015) Fertility preservation success subsequent to concurrent aromatase inhibitor treatment and ovarian stimulation in women with breast cancer. J Clin Oncol. doi: 10.1200/JCO.2014.59.3723 PubMedGoogle Scholar
  56. 56.
    Friedler S, Koc O, Gidoni Y, Raziel A, Ron-El R (2012) Ovarian response to stimulation for fertility preservation in women with malignant disease: a systematic review and meta-analysis. Fertil Steril 97(1):125–133CrossRefPubMedGoogle Scholar
  57. 57.
    Agarwal A, Said TM (2004) Implications of systemic malignancies on human fertility. Reprod Biomed Online 9(6):673–679CrossRefPubMedGoogle Scholar
  58. 58.
    Oktay K, Kim JY, Barad D, Babayev SN (2010) Association of BRCA1 mutations with occult primary ovarian insufficiency: a possible explanation for the link between infertility and breast/ovarian cancer risks. J Clin Oncol 28(2):240–244CrossRefPubMedGoogle Scholar
  59. 59.
    Pal L, Leykin L, Schifren JL, Isaacson KB, Chang YC, Nikruil N, Chen Z, Toth TL (1998) Malignancy may adversely influence the quality and behaviour of oocytes. Hum Reprod 13(7):1837–1840CrossRefPubMedGoogle Scholar
  60. 60.
    Das M, Shehata F, Moria A, Holzer H, Son WY, Tulandi T (2011) Ovarian reserve, response to gonadotropins, and oocyte maturity in women with malignancy. Fertil Steril 96(1):122–125CrossRefPubMedGoogle Scholar
  61. 61.
    Knopman JM, Noyes N, Talebian S, Krey LC, Grifo JA, Licciardi F (2009) Women with cancer undergoing ART for fertility preservation: a cohort study of their response to exogenous gonadotropins. Fertil Steril 91(4 Suppl):1476–1478CrossRefPubMedGoogle Scholar
  62. 62.
    Robertson AD, Missmer SA, Ginsburg ES (2011) Embryo yield after in vitro fertilization in women undergoing embryo banking for fertility preservation before chemotherapy. Fertil Steril 95(2):588–591CrossRefPubMedGoogle Scholar
  63. 63.
    Klock SC, Zhang JX, Kazer RR (2010) Fertility preservation for female cancer patients: early clinical experience. Fertil Steril 94(1):149–155CrossRefPubMedGoogle Scholar
  64. 64.
    Frattarelli JL, Levi AJ, Miller BT, Segars JH (2003) A prospective assessment of the predictive value of basal antral follicles in in vitro fertilization cycles. Fertil Steril 80(2):350–355CrossRefPubMedGoogle Scholar
  65. 65.
    Delvigne A, Rozenberg S (2002) Epidemiology and prevention of ovarian hyperstimulation syndrome (OHSS): a review. Hum Reprod Update 8(6):559–577CrossRefPubMedGoogle Scholar
  66. 66.
    Humaidan P, Kol S, Papanikolaou EG (2011) GnRH agonist for triggering of final oocyte maturation: time for a change of practice? Hum Reprod Update 17(4):510–524CrossRefPubMedGoogle Scholar
  67. 67.
    Engmann L, DiLuigi A, Schmidt D, Nulsen J, Maier D, Benadiva C (2008) The use of gonadotropin-releasing hormone (GnRH) agonist to induce oocyte maturation after cotreatment with GnRH antagonist in high-risk patients undergoing in vitro fertilization prevents the risk of ovarian hyperstimulation syndrome: a prospective randomized controlled study. Fertil Steril 89(1):84–91CrossRefPubMedGoogle Scholar
  68. 68.
    Oktay K, Turkcuoglu I, Rodriguez-Wallberg KA (2010) GnRH agonist trigger for women with breast cancer undergoing fertility preservation by aromatase inhibitor/FSH stimulation. Reprod Biomed Online 20(6):783–788CrossRefPubMedPubMedCentralGoogle Scholar
  69. 69.
    Reddy J, Turan V, Bedoschi G, Moy F, Oktay K (2014) Triggering final oocyte maturation with gonadotropin-releasing hormone agonist (GnRHa) versus human chorionic gonadotropin (hCG) in breast cancer patients undergoing fertility preservation: an extended experience. J Assist Reprod Genet 31(7):927–932. doi: 10.1007/s10815-014-0248-6 CrossRefPubMedPubMedCentralGoogle Scholar
  70. 70.
    McArdle CA, Franklin J, Green L, Hislop JN (2002) Signalling, cycling and desensitisation of gonadotrophin-releasing hormone receptors. J Endocrinol 173(1):1–11CrossRefPubMedGoogle Scholar
  71. 71.
    Blankstein J, Shalev J, Saadon T, Kukia EE, Rabinovici J, Pariente C, Lunenfeld B, Serr DM, Mashiach S (1987) Ovarian hyperstimulation syndrome: prediction by number and size of preovulatory ovarian follicles. Fertil Steril 47(4):597–602CrossRefPubMedGoogle Scholar
  72. 72.
    Papanikolaou EG, Pozzobon C, Kolibianakis EM, Camus M, Tournaye H, Fatemi HM, Van Steirteghem A, Devroey P (2006) Incidence and prediction of ovarian hyperstimulation syndrome in women undergoing gonadotropin-releasing hormone antagonist in vitro fertilization cycles. Fertil Steril 85(1):112–120CrossRefPubMedGoogle Scholar
  73. 73.
    Cakmak H, Fujimoto VY, Zamah AM, Rosen MP, Tran ND, Cedars MI, Rinaudo PF (2012) Metaphase II (MII) oocytes obtained at different time points in the same in vitro fertilization cycle. J Assist Reprod Genet 29(11):1203–1205CrossRefPubMedPubMedCentralGoogle Scholar
  74. 74.
    Baerwald AR, Adams GP, Pierson RA (2012) Ovarian antral folliculogenesis during the human menstrual cycle: a review. Hum Reprod Update 18(1):73–91. doi: 10.1093/humupd/dmr039 CrossRefPubMedGoogle Scholar
  75. 75.
    Xu B, Li Y (2013) Flexible ovarian stimulation in a poor responder: a case report and literature review. Reprod Biomed Online 26(4):378–383. doi: 10.1016/j.rbmo.2012.11.020 CrossRefPubMedGoogle Scholar
  76. 76.
    Kuang Y, Chen Q, Hong Q, Lyu Q, Ai A, Fu Y, Shoham Z (2014) Double stimulations during the follicular and luteal phases of poor responders in IVF/ICSI programmes (Shanghai protocol). Reprod Biomed Online 29(6):684–691. doi: 10.1016/j.rbmo.2014.08.009 CrossRefPubMedGoogle Scholar

Copyright information

© Springer Japan 2016

Authors and Affiliations

  1. 1.Division of Reproductive Endocrinology and Infertility, Department of Obstetrics, Gynecology, and Reproductive SciencesUniversity of California San FranciscoSan FranciscoUSA

Personalised recommendations